Literature DB >> 15332541

[Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0].

Harumi Kaba1, Haruhiko Fukuda, Seiichiro Yamamoto, Yasuo Ohashi.   

Abstract

We evaluated the reliability of CTC v 2.0 based on source documents and also studied the degree of inconsistency in toxicity grading. Five clinical research coordinators from the National Cancer Center Hospital independently reviewed source documents from 17 patients and graded toxicities in the following common adverse events: diarrhea, nausea, stomatitis/pharyngitis, vomiting, febrile neutropenia, infection, infection unknown source, and sensory neuropathy. If grading was already documented on the medical chart, it was masked so that the coordinator could perform the evaluation without information bias. After the completion of toxicity grading, the participating coordinators discussed each case, and a consensus was reached for final toxicity grading. The proportion of agreement for each toxicity criteria are as follows: diarrhea; 0.59 (95%CI 0.35-0.82), nausea; 0.47 (0.23-0.71), stomatitis/pharyngitis; 0.59 (0.35-0.82), vomiting; 0.71 (0.49-0.92), febrile neutropenia; 0.88 (0.73-1.04), infection; 0.82 (0.64-1.01), infection by unknown source; 0.82 (0.64-1.01), sensory neuropathy; 0.65 0.42-0.87). The cause of variability largely depended on the differences in individual clinical assessment, and misunderstanding of toxicity criteria by coordinators has been observed. Even in a single institution environment, variability exists in the toxicity assessment and grading. Good training and education on toxicity assessment using common criteria and development of translated manual, including the interpretation of criteria assessment, may help reduce variability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15332541

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  15 in total

1.  Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4).

Authors:  Michelle A Neben-Wittich; Pamela J Atherton; David J Schwartz; Jeff A Sloan; Patricia C Griffin; Richard L Deming; Jon C Anders; Charles L Loprinzi; Kelli N Burger; James A Martenson; Robert C Miller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

2.  Small-Intestinal Metastasis from Lung Carcinoma.

Authors:  Naotaka Ogasawara; Satoshi Ono; Tomoya Sugiyama; Kazunori Adachi; Yoshiharu Yamaguchi; Shinya Izawa; Masahide Ebi; Yasushi Funaki; Makoto Sasaki; Kunio Kasugai
Journal:  Case Rep Gastroenterol       Date:  2022-03-31

3.  Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.

Authors:  B Vincenzi; D Santini; C Rabitti; R Coppola; B Beomonte Zobel; L Trodella; G Tonini
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

4.  Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling.

Authors:  Yanlan Chai; Juan Wang; Ying Gao; Tao Wang; Fan Shi; Jin Su; Yunyi Yang; Xi Zhou; Liping Song; Zi Liu
Journal:  J Radiat Res       Date:  2014-09-24       Impact factor: 2.724

5.  Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Authors:  David Cella; Mellar P Davis; Sylvie Négrier; Robert A Figlin; M Dror Michaelson; Andrew G Bushmakin; Joseph C Cappelleri; Rickard Sandin; Beata Korytowsky; Claudie Charbonneau; Ewa Matczak; Robert J Motzer
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

6.  Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.

Authors:  Zhao Dehua; Chu Mingming; Wang Jisheng
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

7.  Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.

Authors:  Lei Lei; Wen-Xian Wang; You-Cai Zhu; Jin-Luan Li; Yong Fang; Hong Wang; Wu Zhuang; Yin-Bin Zhang; Li-Ping Wang; Mei-Yu Fang; Chun-Wei Xu; Xiao-Jia Wang; Tang-Feng Lv; Yong Song
Journal:  Cancer Med       Date:  2019-11-06       Impact factor: 4.452

8.  Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.

Authors:  Rui-Min Ma; Chuan-Zhi Chen; Wei Zhang; Jie You; Du-Ping Huang; Gui-Long Guo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis.

Authors:  Yunyun Lu; Yun Fan
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

10.  Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.

Authors:  Lisa M Wintner; Johannes M Giesinger; Monika Sztankay; Andrew Bottomley; Bernhard Holzner
Journal:  Trials       Date:  2020-10-13       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.